Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.

CEO

Douglas Swirsky

Employees

Country

United States

ISIN

US67577R1023

Listings

0 Comments

Share your thoughts

FAQ

What is Opus Genetics stock price today?▼

The current price of OCUP is $1.17 USD — it has decreased by -12.03% in the past 24 hours. Watch Opus Genetics stock price performance more closely on the chart.

What is Opus Genetics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Opus Genetics stocks are traded under the ticker OCUP.

What is Opus Genetics revenue for the last year?▼

Opus Genetics revenue for the last year amounts to 38.1M USD.

What is Opus Genetics net income for the last year?▼

OCUP net income for the last year is -19.97M USD.

How many employees does Opus Genetics have?▼

As of September 06, 2026, the company has 14 employees.

In which sector is Opus Genetics located?▼

Opus Genetics operates in the Technology sector.

When did Opus Genetics complete a stock split?▼

The last stock split for Opus Genetics was on November 06, 2020 with a ratio of 1:4.

Where is Opus Genetics headquartered?▼

Opus Genetics is headquartered in Rockville, United States.